UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 40

Sortiert nach

317 Safety and efficacy results from a phase 1 dose-escalation trial of the parp inhibitor talazoparib (bmn-673) in combination with either temozolomide or irinotecan in patients with advanced malignancies

European journal of cancer (1990), 2015-09, Vol.51, p.S60-S60

2015

Volltextzugriff (PDF)

2014 Final analysis of the PEAK trial: Overall survival (OS) and tumour responses during first-line treatment with mFOLFOX6 + either panitumumab (pmab) or bevacizumab (bev) in patients (pts) with metastatic colorectal carcinoma (mCRC)

European journal of cancer (1990), 2015-09, Vol.51, p.S332-S333

2015

Volltextzugriff (PDF)

439TiP A phase II (ph2), randomized study of magrolimab with bevacizumab and FOLFIRI in previously treated patients with advanced inoperable metastatic colorectal cancer (mCRC)

Annals of oncology, 2022-09, Vol.33, p.S735

2022

Volltextzugriff (PDF)

44P BOLD-100-001: A phase II study of BOLD-100 in combination with FOLFOX in advanced mCRC patients that have failed at least two prior lines of therapy

Annals of oncology, 2024-06, Vol.35, p.S22-S22

2024

Volltextzugriff (PDF)

77P Chronologic improvement in survival of first-line oxaliplatin based chemotherapy + targeted therapy for metastatic colorectal cancer (mCRC): Analysis of the ARCAD database

Annals of oncology, 2024-06, Vol.35, p.S38-S38

2024

Volltextzugriff (PDF)

736MO Personalized, off-the-shelf KRAS neoantigen-specific immunotherapy for the treatment of advanced solid tumors: Clinical benefit associated with decreases in ctDNA (SLATE-KRAS)

Annals of oncology, 2022-09, Vol.33, p.S880

2022

Volltextzugriff (PDF)

44P Biomarker analysis from a phase Ib, multicenter, open-label clinical trial of talimogene laherparepvec (T-VEC) injected (inj) into metastatic and primary liver tumors

Annals of oncology, 2021-12, Vol.32, p.S1390-S1391

2021

Volltextzugriff (PDF)

A Randomized, Double-Blind, Placebo-Controlled Phase II Study of the Efficacy and Safety of Monotherapy Ontuxizumab (MORAb-004) Plus Best Supportive Care in Patients with Chemorefractory Metastatic Colorectal Cancer

Clinical cancer research, 2018-01, Vol.24 (2), p.316-325

2018

Volltextzugriff (PDF)

Responses and durability of clinical benefit in pancreatic ductal adenocarcinoma (PDAC) patients treated with pegilodecakin (AM0010) in combination with 5-FU/LV and oxaliplatin (FOLFOX)

Annals of oncology, 2018-10, Vol.29, p.viii406-viii406

2018

Volltextzugriff (PDF)

Overall survival and immunologic responses in metastatic pancreatic adenocarcinoma (PDAC) on PEGylated human IL-10 (AM0010) with 5-FU/LV and oxaliplatin (FOLFOX)

Annals of oncology, 2017-09, Vol.28, p.v254-v254

2017

Volltextzugriff (PDF)

Long-Term Data for Endoscopic Ultrasound (EUS) and Percutanous (Pta) Guided Intratumoral Tnferade Gene Delivery Combined with Chemoradiation in the Treatment of Locally Advanced Pancreatic Cancer (LAPC)

Gastrointestinal endoscopy, 2006, Vol.63 (5), p.AB93-AB93

2006

Volltextzugriff (PDF)

Phase Ib study of talimogene laherparepvec in combination with atezolizumab in patients with triple negative breast cancer and colorectal cancer with liver metastases

ESMO open, 2023-04, Vol.8 (2), p.100884-100884, Article 100884

2023

Volltextzugriff (PDF)

PD-014 First-line treatment with modified FOLFOX6 (mFOLFOX6) + panitumumab or bevacizumab in patients with RAS/BRAF wild-type (WT) metastatic colorectal carcinoma (mCRC)

Annals of oncology, 2015-06, Vol.26, p.iv105

2015

Volltextzugriff (PDF)

3019 POSTER Association of gene copy number (GCN) of the epidermal growth factor receptor (EGFr) and clinical outcome in patients (pts) with metastatic colorectal cancer (mCRC) treated with panitumumab monotherapy

European journal of cancer supplements, 2007, Vol.5 (4), p.241-241

2007

Volltextzugriff (PDF)

3010 ORAL Final overall survival (OS) results of CONFIRM 1 (CF1), a randomized, double-blind, placebo-controlled phase III trial in patients with metastatic adenocarcinoma of the colon or rectum (mCRC) receiving first line chemotherapy with oxaliplatin/5-fluorouracil/Leucovorin (FOLFOX 4) and PTK787/ZK 222584 (PTK/ZK) or placebo (PBO)

European journal of cancer supplements, 2007, Vol.5 (4), p.238-238

2007

Volltextzugriff (PDF)

3014 (Presidential session, Tue 25 Sep 12.30–14.30) ORAL Association of somatic KRAS gene mutations and clinical outcome in patients (pts) with metastatic colorectal cancer (mCRC) receiving panitumumab monotherapy

European journal of cancer supplements, 2007, Vol.5 (4), p.239-239

2007

Volltextzugriff (PDF)

Proton Pump Inhibitor (Ppis) Therapy May Impair Capecitabine (Cape) Efficacy in Metastatic Gastroesophageal Cancer (Gec), Results from the Trio-013/Logic Trial

Annals of oncology, 2014-09, Vol.25, p.iv211

2014

Volltextzugriff (PDF)

Low-dose trimetrexate glucuronate and protracted5-fluorouracil infusion in previously untreated patients with advanced pancreatic cancer

Annals of oncology, 2002-04, Vol.13 (4), p.582-588

2002

Volltextzugriff (PDF)

620PDPROTON PUMP INHIBITOR (PPIS) THERAPY MAY IMPAIR CAPECITABINE (CAPE) EFFICACY IN METASTATIC GASTROESOPHAGEAL CANCER (GEC), RESULTS FROM THE TRIO-013/LOGIC TRIAL

Annals of oncology, 2014-09, Vol.25 (suppl_4), p.iv211-iv212

2014

Volltextzugriff (PDF)

A patient satisfaction study of cT colography (Virtual colonoscopy) and colonoscopy

Gastrointestinal endoscopy, 1997, Vol.45 (4), p.AB108-AB108

1997

Volltextzugriff (PDF)

Influence of HLA-B57 on clinical presentation and viral control during acute HIV-1 infection

AIDS (London), 2003-12, Vol.17 (18), p.2581-2591

2003

Volltextzugriff (PDF)

Cellular immune responses and viral diversity in individuals treated during acute and early HIV-1 infection

The Journal of experimental medicine, 2001-01, Vol.193 (2), p.169-180

2001

Volltextzugriff (PDF)

The lysosomal endopeptidases Cathepsin D and L are selective and effective proteases for the middle‐down characterization of antibodies

The FEBS journal, 2021-09, Vol.288 (18), p.5389-5405

2021

Volltextzugriff (PDF)

Revisiting the utility of identifying nuclear grooves as unique nuclear changes by an object detector model

Journal of Pathology and Translational Medicine, 2024, 58(3), , pp.117-126

2024

Volltextzugriff (PDF)

Near-infrared nanospectroscopy using a low-noise supercontinuum source

APL photonics, 2021-06, Vol.6 (6), p.066106-066106-10

2021

Volltextzugriff (PDF)

1 – 25 von 40

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(37)
Mit Volltextzugriff
(39)

Publikationsform

Artikel
(40)

Sprache

Englisch
(40)
Japanisch
(3)

Erscheinungsjahr

n.n

Thema

Science & Technology
(14)
Life Sciences & Biomedicine
(9)
Humans
(6)
Female
(5)
Hematology, Oncology And Palliative Medicine
(5)
Adult
(4)
Male
(4)
Original
(4)
Physical Sciences
(4)
Physics
(4)
Fatigue
(3)
Hiv Infections - Immunology
(3)
Hiv-1 - Genetics
(3)
Human Immunodeficiency Virus 1
(3)
Immunology
(3)
Materials Science
(3)
Oncology
(3)
Acute Disease
(2)
Antitumor Treatment
(2)
Base Sequence
(2)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

317 Safety and efficacy results from a phase 1 dose-escalation trial of the parp inhibitor talazoparib (bmn-673) in combination with either temozolomide or irinotecan in patients with advanced malignancies

2014 Final analysis of the PEAK trial: Overall survival (OS) and tumour responses during first-line treatment with mFOLFOX6 + either panitumumab (pmab) or bevacizumab (bev) in patients (pts) with metastatic colorectal carcinoma (mCRC)

439TiP A phase II (ph2), randomized study of magrolimab with bevacizumab and FOLFIRI in previously treated patients with advanced inoperable metastatic colorectal cancer (mCRC)

44P BOLD-100-001: A phase II study of BOLD-100 in combination with FOLFOX in advanced mCRC patients that have failed at least two prior lines of therapy

77P Chronologic improvement in survival of first-line oxaliplatin based chemotherapy + targeted therapy for metastatic colorectal cancer (mCRC): Analysis of the ARCAD database

736MO Personalized, off-the-shelf KRAS neoantigen-specific immunotherapy for the treatment of advanced solid tumors: Clinical benefit associated with decreases in ctDNA (SLATE-KRAS)

44P Biomarker analysis from a phase Ib, multicenter, open-label clinical trial of talimogene laherparepvec (T-VEC) injected (inj) into metastatic and primary liver tumors

A Randomized, Double-Blind, Placebo-Controlled Phase II Study of the Efficacy and Safety of Monotherapy Ontuxizumab (MORAb-004) Plus Best Supportive Care in Patients with Chemorefractory Metastatic Colorectal Cancer

Responses and durability of clinical benefit in pancreatic ductal adenocarcinoma (PDAC) patients treated with pegilodecakin (AM0010) in combination with 5-FU/LV and oxaliplatin (FOLFOX)

Overall survival and immunologic responses in metastatic pancreatic adenocarcinoma (PDAC) on PEGylated human IL-10 (AM0010) with 5-FU/LV and oxaliplatin (FOLFOX)

Long-Term Data for Endoscopic Ultrasound (EUS) and Percutanous (Pta) Guided Intratumoral Tnferade Gene Delivery Combined with Chemoradiation in the Treatment of Locally Advanced Pancreatic Cancer (LAPC)

Phase Ib study of talimogene laherparepvec in combination with atezolizumab in patients with triple negative breast cancer and colorectal cancer with liver metastases

PD-014 First-line treatment with modified FOLFOX6 (mFOLFOX6) + panitumumab or bevacizumab in patients with RAS/BRAF wild-type (WT) metastatic colorectal carcinoma (mCRC)

3019 POSTER Association of gene copy number (GCN) of the epidermal growth factor receptor (EGFr) and clinical outcome in patients (pts) with metastatic colorectal cancer (mCRC) treated with panitumumab monotherapy

3014 (Presidential session, Tue 25 Sep 12.30–14.30) ORAL Association of somatic KRAS gene mutations and clinical outcome in patients (pts) with metastatic colorectal cancer (mCRC) receiving panitumumab monotherapy

Proton Pump Inhibitor (Ppis) Therapy May Impair Capecitabine (Cape) Efficacy in Metastatic Gastroesophageal Cancer (Gec), Results from the Trio-013/Logic Trial

Low-dose trimetrexate glucuronate and protracted5-fluorouracil infusion in previously untreated patients with advanced pancreatic cancer

620PDPROTON PUMP INHIBITOR (PPIS) THERAPY MAY IMPAIR CAPECITABINE (CAPE) EFFICACY IN METASTATIC GASTROESOPHAGEAL CANCER (GEC), RESULTS FROM THE TRIO-013/LOGIC TRIAL

A patient satisfaction study of cT colography (Virtual colonoscopy) and colonoscopy

Influence of HLA-B57 on clinical presentation and viral control during acute HIV-1 infection

Cellular immune responses and viral diversity in individuals treated during acute and early HIV-1 infection

The lysosomal endopeptidases Cathepsin D and L are selective and effective proteases for the middle‐down characterization of antibodies

Revisiting the utility of identifying nuclear grooves as unique nuclear changes by an object detector model

Near-infrared nanospectroscopy using a low-noise supercontinuum source

Suchergebnisse filtern